German drug discount deals attacked

2 September 2007

Drug discount deals between German public-sector health funds (Krankenkassen) and drug companies pose considerable risks for patients, according to experts invoked by the German Association for Insured and Patients (DGVP). The association says that discount drugs are affected by delays in some 20% of cases of prescription and this means that security of supply - a key issue in German drug politics - is insufficiently safeguarded.

The DGVP has called on the health funds to focus on the welfare of patients and not on the lowest-cost drugs. The discount deals guarantee the drugmakers a certain price level so they are more profitable than the lowest-price products in their ranges. Patients also benefit because they are charged less.

Funds could save "at least 83M euros a year" with set-price deal

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight